1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
10qk
10qk
Articles 

United Therapeutics Corp. Reports Operating Results (10-Q)

November 01, 2012 | About:

United Therapeutics Corp. (NASDAQ:UTHR) filed Quarterly Report for the period ended 2012-09-30.

United Therapeutics Corporation has a market cap of $2.34 billion; its shares were traded at around $45.67 with a P/E ratio of 9.7 and P/S ratio of 3.2.

Highlight of Business Operations:

In September 2011, we were awarded a cost plus fixed fee contract with an aggregate value of up to $45.0 million under a Broad Agency Announcement from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) for studies directed at the development of a broad spectrum antiviral drug based on our glycobiology antiviral platform. Under the contracts base period of forty-two months, we will receive $10.6 million in funding. In addition, there are eight milestone-based options to expand the project and funding under the contract. In August 2012, we received a contract modification exercising two of the above-mentioned milestone-based options, increasing total contract funding by $8.7 million. We recognize revenue on this contract to the extent of costs incurred, plus a proportionate amount of fee earned.

Accounts receivable at September 30, 2012, were $108.9 million, compared to $88.7 million at December 31, 2011. The increase in accounts receivable of $20.3 million was attributable to the increase in sales during the quarter ended September 30, 2012 as compared to the quarter ended December 31, 2011.

Accrued expenses were $87.6 million at September 30, 2012, compared to $57.2 million at December 31, 2011. The increase of $30.4 million consisted substantially of the following elements: (1) a $15.0 million accrual for non-refundable license fees; (2) a $4.3 million increase in accrued royalties and rebates corresponding to the increase in sales; (3) a $4.0 million increase in accrued payroll-related expenses due to the growth in headcount during the year; and (4) a $6.2 million increase in various other accruals relating to our operations.

General and administrative. The increase in general and administrative expenses of $8.0 million for the quarter ended September 30, 2012 compared to the same quarter in 2011 was driven mainly by a $3.7 million increase in grants to unaffiliated, not-for-profit organizations that provide financial assistance to PAH patients and a $2.6 million increase in depreciation and operating expenses as a result of the expansion of our corporate headquarters in Maryland and our facilities in North Carolina.

General and administrative. The increase in general and administrative expenses of $14.6 million for the nine months ended September 30, 2012 compared to the same period in 2011 was driven by the following: (1) the recognition of a $6.8 million impairment loss relating to a contract-based intangible asset as described in Note 6Goodwill and Other Intangible Assets to the consolidated financial statements contained in this Quarterly Report on Form 10-Q; (2) an increase of $3.8 million in depreciation as a result of the expansion of our corporate headquarters in Maryland and our facilities in North Carolina; and (3) a $3.5 million increase in grants to unaffiliated, not-for-profit organizations that provide financial assistance to PAH patients.

Read the The complete Report

About the author:

10qk
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 3.0/5 (2 votes)

Comments

Please leave your comment:


Select portfolio(s):

  • Loading...

Why you are interested?

Your selection and notes will be stored in your portfolio.

Login to add portfolio
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK